Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.53 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.50 |
| ▸ | CTSA | P10619 | 10/20 | 0.48 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.48 |
| ▸ | TNF | P01375 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.45 |
| ▸ | PTPRC | P08575 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7227941 | 1.00 | MME (0.53) | MMEMMEL1PPARGPPARACTSA | |
| Hydrochloric Acid SCHEMBL6607511 | 0.99 | MME (0.52) | MMEMMEL1PPARGPPARACTSA | |
| Hydrochloric Acid SCHEMBL7229517 | 0.86 | PDE4A (0.46) | MMEMMEL1PPARGPPARACTSA | |
| SCHEMBL20546324 | 0.85 | CTSA (0.61) | CTSA | |
| SCHEMBL20546326 | 0.85 | CTSA (0.61) | CTSA | |
| SCHEMBL20545890 | 0.85 | CTSA (0.50) | CTSATNF | |
| SCHEMBL20545888 | 0.85 | CTSA (0.50) | CTSATNF | |
| SCHEMBL6784104 | 0.84 | ITGB1 (0.49) | CTSA | |
| SCHEMBL7227091 | 0.84 | ITGB1 (0.49) | CTSA | |
| SCHEMBL7235672 | 0.83 | CTSA (0.50) | CTSA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1034164-B1 | SUBSTITUTED BETA-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS | MERCK & CO INC (US) | 2004-05-19 | — | — | EP | disclosed |
| US-6734311-B2 | ANTIINFLAMMATORY AGENTS; ALZHEIMER'S DISEASE; CARDIOVASCULAR DISORDERS | MERCK & CO., INC. | 2004-05-11 | — | — | US | disclosed |
| US-6645939-B1 | Very late antigen-4 (VLA) integrin antagonists; antiallergens, antiasthmatics, and antiinflammatory agents; multiple sclerosis, autoimmune disease treatment | MERCK & CO., INC. | 2003-11-11 | — | — | US | disclosed |
| US-20030092746-A1 | Substituted amidine derivatives as inhibitors of cell adhesion | MERCK & CO., INC. | 2003-05-15 | — | — | US | disclosed |
| US-6482840-B2 | TREATMENT OF AIDS-RELATED DEMENTIA, ALLERGIC CONJUNCTIVITIS, ALLERGIC RHINITIS, ALZHEIMER'S DISEASE, ASTHMA, ATHEROSCLEROSIS, AUTOLOGOUS BONE MARROW TRANSPLANTATION, INFLAMMATORY LUNG DISEASES, MENINGITIS, MULTIPLE SCLEROSIS | MERCK & CO., INC. | 2002-11-19 | — | — | US | disclosed |
| US-6403584-B1 | CONJUNCTIVITIS, ALLERGIC RHINITIS, ALZHEIMER'S DISEASE, ASTHMA, ATHEROSCLEROSIS, AUTOLOGOUS BONE MARROW TRANSPLANTATION, ANTIINFLAMMATORY, ETC | MERCK & CO., INC. | 2002-06-11 | — | — | US | disclosed |
| US-6353099-B1 | USED FOR PREVENTION OR TREATMENT OF DISEASES, DISORDERS, CONDITIONS OR SYMPTOMS MEDIATED BY CELL ADHESION IN MAMMAL | MERCK & CO., INC. | 2002-03-05 | — | — | US | disclosed |
| US-20020010199-A1 | Substituted cyclic amidine derivatives as inhibitors of cell adhesion | MERCK SHARP & DOHME CORP. | 2002-01-24 | — | — | US | disclosed |
| EP-1034164-A4 | SUBSTITUTED BETA-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS | MERCK & CO INC (US) | 2001-07-11 | — | — | EP | disclosed |
| WO-2001014328-A2 | SUBSTITUTED UREAS AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 2001-03-01 | — | — | WO | disclosed |
| WO-2000071572-A1 | SUBSTITUTED BETA-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 2000-11-30 | — | — | WO | disclosed |
| EP-1034164-A1 | SUBSTITUTED BETA-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS | Merck & Co., Inc. (US) | 2000-09-13 | — | — | EP | disclosed |
| WO-1999026921-A1 | SUBSTITUTED β-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 1999-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092746-A1 | Substituted amidine derivatives as inhibitors of cell adhesion | VCAM1, CD4, ICAM1 | MME 851/4885MMEL1 1943/4885PPARG 3703/4885 |
| US-20020010199-A1 | Substituted cyclic amidine derivatives as inhibitors of cell adhesion | VCAM1, CD4, ICAM1 | MME 1142/4885MMEL1 2308/4885PPARG 3977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.